
**SUPPLEMENTAL MATERIAL**

**Supplementary Figure 1.** Antimicrobial Stewardship Custom Electronic Health Record Smartform.


C:\Users\UCW7H00471\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Word\ASP navigator (1).tiff



**Supplementary Figure 2.** Example iVent Documentation in the Electronic Health Record.



**Supplementary Figure 3.** Indication-Driven Order Panel in the Electronic Health Record for a) Cefazolin, b) Meropenem, and c) Piperacillin-tazobactam.


a)



b) c) 

**Supplementary Figure 4.** Percentage of Prospective Audit with a Recommendation.

Note. The bolded line reflects the mean during the time period. The dashed lines represent the upper and lower control limits during the time period.



**Supplementary Table 1.** iVent Type

|  |
| --- |
| **iVent type** |
| Renal dose adjustment |
| Dose/frequency |
| Medication not indicated |
| Medication indicated |
| Alternative therapy |
| Decrease medication frequency |
| Discontinue medication |
| IV to PO |

Note. IV, intravenous; PO, per os

**Supplemental Table 2.** Infectious Problems Associated with PAF Recommendations pre-IDOE versus IDOE.

|  |  |  |
| --- | --- | --- |
| **Infectious Problem** | **Pre-IDOE (N = 246), No. (%)** | **IDOE (N = 166), No. (%)** |
| Bacteremia | 19 (8) | 12 (7) |
| Bone and joint infection | 8 (3) | 1 (1) |
| CNS infection | 2 (1) | 3 (2) |
| Febrile neutropenia | 13 (5) | 8 (5) |
| Gastrointestinal/IAI | 32 (13) | 26 (16) |
| Non identified | 6 (2) | 3 (2) |
| Other | 19 (8) | 26 (16) |
| Prophylaxis | 51 (21) | 25 (15) |
| Respiratory infection | 41 (17) | 32 (19) |
| Sepsis | 43 (18) | 25 (15) |
| Urinary tract infection | 12 (5) | 5 (3) |

Note. CNS, central nervous system; IAI, intra-abdominal infection

**Supplemental Table 3.** PAF Recommendation Types pre-IDOE versus IDOE

|  |  |  |
| --- | --- | --- |
| **Recommendation type** | **Pre-IDOE**  **N = 246, No. (%)** | **IDOE**  **N = 166, No. (%)** |
| Change agent | 77 (31) | 48 (29) |
| Clarify | 19 (8) | 20 (12) |
| Duration modification | 28 (11) | 22 (13) |
| IV to PO | 25 (10) | 8 (5) |
| Optimize dose or frequency | 26 (11) | 15 (9) |
| Other | 36 (15) | 20 (12) |
| Stop | 35 (14) | 33 (20) |

Note. IDOE, indication-driven order entry; IV, intravenous; PO, per os